Abivax
5, rue de la Baume
Paris
75008
France
Tel: 33-0-1-53-83-08-41
Website: http://www.abivax.com/en/
Email: info@abivax.com
100 articles with Abivax
-
ABIVAX Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50mg ABX464 in Rheumatoid Arthritis
6/23/2021
Abivax SA announces excellent top-line results of the induction phase of its phase 2a clinical study of ABX464 administered in combination with methotrexate for the treatment of active moderate to severe rheumatoid arthritis.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Abivax Suspends Trading of its Shares Until the Publication of ABX464 Phase 2b Results in Ulcerative Colitis
5/24/2021
Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the suspension of the trading of its shares until the publication of the results of its phase 2b study for the treatment of ulcerative colitis with ABX464.
-
Abivax publishes Universal Registration Document 2021 'Document d'Enregistrement Universel'
4/30/2021
Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces the publication of its 2021 Universal Registration Document, filed with the French Financial Market Authorities, Autorité des Marchés Financiers, on April 30, 2021.
-
Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis
4/19/2021
Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that it will host a key opinion leader (KOL) webinar on ABX464 for the treatment of ulcerative colitis (UC).
-
Abivax Reports 2020 Financial Results and Operations Update
3/31/2021
Recruitment completed in ABX464 phase 2b ulcerative colitis and phase 2a rheumatoid arthritis studies; top-line results for both studies will become available in Q2 2021 Excellent short- and long-term efficacy and safety data for 50 mg once-daily oral ABX464 in ulcerative colitis phase 2a study published in Gastroenterology Recruitment for dose escalation phase of ABX196 proof-of-concept study in hepatocellular carcinoma to be completed shortly
-
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology'
3/3/2021
Peer-reviewed article confirms the quality and robustness of clinical data and the good safety and durable efficacy of once daily oral ABX464 in moderate to severe ulcerative colitis (UC) patients Recruitment of subsequent phase 2b induction study in 254 patients with ABX464 in UC completed in December 2020 and top-line results are expected in Q2 2021 Abivax is preparing to move its lead drug-candidate ABX464 into a phase 3 clinical program in ulcerative colitis and to initiate a phase
-
Abivax Appoints Dr. Sophie Biguenet, M.D., as Chief Medical Officer
3/1/2021
Dr Sophie Biguenet joins Abivax on March 1 As CMO, Sophie Biguenet will drive Abivax main clinical program of ABX464 for the treatment of inflammatory bowel diseases (IBD) into phase 3 testing in 2021
-
Truffle Capital Reports Outstanding 2020 Stock Market Performance for Its Listed BioMedTech Portfolio Companies
2/1/2021
Three companies founded or co-founded by Truffle represent 30% of the total valuation of the highest BioMedTech market caps of Euronext Paris. They are also among the 2020 top stock performers.
-
BioSpace Global Roundup: Ayala Moves Forward with Desmoid Tumor Asset in Phase II/III Study
1/7/2021
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business. -
Abivax to Present at the 39th Annual J.P. Morgan Healthcare Conference Ahead of Major Clinical Milestones
12/21/2020
Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday,
-
Global Roundup: Overland Pharma Launches in China to Provide Access to Breakthrough Therapies
12/10/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021
12/9/2020
Pivotal ABX464 clinical trials ongoing or planned for three indications: Ulcerative colitis, Crohns disease and Covid-19 Four phase 1 studies are being initiated to generate complementary data to support the late-stage development program of ABX464 Discussions planned with regulatory agencies in Europe, the US and Japan to seek recommendations and agreement with the phase 3 development approach in ulcerative colitis and Crohns disease
-
Abivax 2021 Financial Communication Calendar
12/3/2020
Abivax (Euronext Paris:FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar. Thursday, April 1, 2021 Publication of financial statements as of December 31, 2020 Friday, April 30, 2021 Publication and release of the 2020 annual financial report Friday, June 4, 2021
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
Abivax Completes Recruitment of ABX464 Phase 2b Induction Study in Ulcerative Colitis
11/30/2020
Recruitment of 232 patients completed ahead of schedule with minimal impact by the Covid-19 pandemic
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Abivax Announces the Success of Its Oversubscribed Capital Increase of EUR 28m at Market Price
10/29/2020
Subscribed by top-tier U.S. and European biotech investors (12 investors in total, 55% of funds raised from European investors, 45% from the U.S.)
-
BioSpace Global Roundup, Oct. 15
10/15/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.